Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
Would your treatment recommendations change for patients with ESRD or on dialysis?
Related Questions
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
What is your approach to treatment of relapsed, high-risk MDS with TP53 mutation in a patient that is not considered a transplant candidate?
How do you manage ocular hemorrhages while on acalabrutinib for CLL?
Does treating CLL reduce the risk of non-melanoma skin cancers?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
In patients with AML who achieve a CR with HMA/Ven, what is the optimal dose and schedule for venetoclax for further cycles?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
How do you approach c-KIT mutated, core binding factor (CBF) AML?